Antibody therapy for the management of severe asthma with eosinophilic inflammation.

about

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

Item

http://www.wikidata.org/entity/Q47773104

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@en

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@nl

type

Item

label

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@en

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@nl

prefLabel

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@en

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@nl

P1476

Antibody therapy for the management of severe asthma with eosinophilic inflammation.

@en

P2093

Ken Ohta

http://www.w3.org/2001/XMLSchema#string

Maho Suzukawa

http://www.w3.org/2001/XMLSchema#string

Shin Ohta

http://www.w3.org/2001/XMLSchema#string

P2860

Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma

IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13

Japanese guidelines for adult asthma 2017.

Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective.

Enhanced innate type 2 immune response in peripheral blood from patients with asthma

Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production.

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.

Interleukin (IL)-33: new therapeutic target for atopic diseases.

Identification of IgE.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

P304

337-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INTIMM/DXX045

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hiroyuki Nagase

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28910970

http://www.w3.org/2001/XMLSchema#string

P921

asthma